Antibodies to the Spike Protein Receptor-Binding Domain of SARS-CoV-2 at 4–13 Months after COVID-19

• Published in: Journal of clinical medicine Vol. 11; no. 14; p. 4053
• Main Authors: Kolosova, Evgeniia A., Shaprova, Olga N., Shanshin, Daniil V., Nesmeyanova, Valentina S., Merkuleva, Iuliia A., Belenkaya, Svetlana V., Isaeva, Anastasiya A., Nikitin, Artem O., Volosnikova, Ekaterina A., Nikulina, Yuliya A., Nikonorova, Marina A., Shcherbakov, Dmitry N., Elchaninova, Svetlana A.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.07.2022; MDPI
• Subjects: Antibodies; Chromatography; Clinical medicine; Cloning; Coronaviruses; COVID-19; Enzymes; Infections; Medical research; Plasmids; Proteins; Severe acute respiratory syndrome coronavirus 2; Sodium; Vectors (Biology); United States > US; Latvia; Russia; COVID-19; SARS-CoV-2; pneumonia; receptor-binding domain; spike protein; antibodies; age

Identification of factors behind the level and duration of persistence of the SARS-CoV-2 antibodies in the blood is assumed to set the direction for studying humoral immunity mechanisms against COVID-19, optimizing the strategy for vaccine use, antibody-based drugs, and epidemiological control of CO...